Sensen Cheng1,2, Jinsong Zheng2, Jingyan Zhu3, Chao Xie2, Xia Zhang2, Xiao Han2, Bao Song2, Yuan Ma1,2, Jie Liu2. 1. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Jinan, Shandong - China. 2. Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong - China. 3. Department of Oncology, Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong - China.
Abstract
BACKGROUND: PD-1 and its ligand PD-L1 belong to the co-inhibition molecules, which can downregulate immune responses. The PD-L1 polymorphism and the level of soluble PD-L1 (sPD-L1) were investigated in non-small cell lung cancer (NSCLC). METHODS: A total of 288 NSCLC patients and 300 controls were enrolled. An A/C polymorphism at position 8923 in the PD-L1 gene was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: The prevalence of the 8923C allele was significantly higher in NSCLC patients than controls (10.2% versus 5.3%, p = 0.002, odds ratio 2.03, 95% confidence interval 1.30-3.17; data were adjusted for age and sex). NSCLC patients also showed increased plasma levels of sPD-L1 compared to controls (1.92 ng/mL versus 0.91 ng/mL, p<0.001). Furthermore, lung adenocarcinoma patients had higher sPD-L1 levels than patients with squamous cell carcinoma (p<0.01). However, no association was observed between the different genetic variants and plasma concentrations of sPD-L1. CONCLUSIONS: The PD-L1 8923A/C polymorphism could be associated with increased susceptibility to NSCLC. Plasma levels of sPD-L1 are significantly increased in NSCLC patients, especially those with adenocarcinoma.
BACKGROUND:PD-1 and its ligand PD-L1 belong to the co-inhibition molecules, which can downregulate immune responses. The PD-L1 polymorphism and the level of soluble PD-L1 (sPD-L1) were investigated in non-small cell lung cancer (NSCLC). METHODS: A total of 288 NSCLCpatients and 300 controls were enrolled. An A/C polymorphism at position 8923 in the PD-L1 gene was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: The prevalence of the 8923C allele was significantly higher in NSCLCpatients than controls (10.2% versus 5.3%, p = 0.002, odds ratio 2.03, 95% confidence interval 1.30-3.17; data were adjusted for age and sex). NSCLCpatients also showed increased plasma levels of sPD-L1 compared to controls (1.92 ng/mL versus 0.91 ng/mL, p<0.001). Furthermore, lung adenocarcinomapatients had higher sPD-L1 levels than patients with squamous cell carcinoma (p<0.01). However, no association was observed between the different genetic variants and plasma concentrations of sPD-L1. CONCLUSIONS: The PD-L18923A/C polymorphism could be associated with increased susceptibility to NSCLC. Plasma levels of sPD-L1 are significantly increased in NSCLCpatients, especially those with adenocarcinoma.
Authors: Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay Journal: Cancer Immunol Immunother Date: 2018-12-18 Impact factor: 6.968
Authors: Kentaro Minagawa; Muhammad O Jamil; Mustafa Al-Obaidi; Larisa Pereboeva; Donna Salzman; Harry P Erba; Lawrence S Lamb; Ravi Bhatia; Shin Mineishi; Antonio Di Stasi Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: Vishwajith Sridharan; Danielle N Margalit; Stephanie A Lynch; Mariano Severgnini; Jun Zhou; Nicole G Chau; Guilherme Rabinowits; Jochen H Lorch; Peter S Hammerman; F Stephen Hodi; Robert I Haddad; Roy B Tishler; Jonathan D Schoenfeld Journal: Br J Cancer Date: 2016-07-05 Impact factor: 7.640